AIM ImmunoTech Inc. (AIM) - Dilution Analysis

8-K filing: AIM ImmunoTech Inc. entered into an agreement to issue and sell 7,519,351 shares of common stock and concurrent warrants in a registered direct offering and private placement. ($2.4M proceeds)

10-Q filing | 14.6M shares outstanding

8-K filing: AIM ImmunoTech Inc. closed an inducement transaction involving the exercise of existing warrants for 7,451,920 shares of common stock and the issuance of new Class H warrants to purchase 14,903,840 shares. ($3.6M proceeds)

8-K filing: AIM ImmunoTech Inc. entered into a warrant exercise inducement offer letter agreement with holders of existing warrants to purchase common stock at a reduced exercise price of $0.48 per share, and will issue new warrants to purchase additional shares of common stock. ($4.2M proceeds)

S-1/A filing: This S-1/A filing describes a rights offering where holders of common stock and certain outstanding options and warrants receive non-transferable subscription rights to purchase units, each consisting of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock, at a subscription price of $1,000 per unit.

S-1/A filing: This S-1/A filing details a rights offering for units consisting of Series G Convertible Preferred Stock and warrants, along with common stock issuable upon conversion or exercise.

10-Q filing | 2.9M shares outstanding

10-Q filing | 2.7M shares outstanding

S-1/A filing: This S-1/A filing from AIM ImmunoTech Inc. describes an offering of up to 1,052,631 units, each consisting of one share of common stock (or a pre-funded warrant in lieu of a share), one Class E warrant, and one Class F warrant, at an assumed price of $9.50 per unit, along with associated placement agent warrants.

S-1/A filing: AIM ImmunoTech Inc. is offering up to 1,052,631 units, each consisting of one share of common stock, one Class E warrant and one Class F warrant, or pre-funded warrants in lieu of common stock. They are also offering placement agent warrants.

S-3/A filing: AIM ImmunoTech Inc. may offer and sell common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, and/or debt securities for total gross proceeds of up to $100,000,000.

8-K filing: Stock split 1-for-100 | Outstanding: 70,329,869 → 703,298

10-Q filing | 70.3M shares outstanding

S-3 filing: AIM ImmunoTech Inc. is offering common stock, preferred stock, purchase contracts, subscription rights, depositary shares, and debt securities for total gross proceeds of up to $100,000,000.

10-K filing | 72.3M shares outstanding

S-1/A filing: This S-1/A filing dated 2025-02-07 is for an offering of up to 49,701,789 units, each consisting of one share of common stock, one Class E warrant, and one Class F warrant, and up to 2,485,089 placement agent warrants. The assumed public offering price is $0.2012 per Unit.

S-1/A filing: AIM ImmunoTech Inc. is offering up to 49,701,789 units, each consisting of one share of common stock, one Class E warrant to purchase one share of common stock and one Class F warrant to purchase one share of common stock, and also offering up to 2,485,089 Placement Agent Warrants to purchase up to 2,485,089 Shares of Common Stock.

S-1 filing: AIM ImmunoTech Inc. is offering Units, each consisting of one share of common stock or one pre-funded warrant, one Class A warrant and one Class B warrant. Maxim Group LLC is the placement agent.

S-1 filing: This S-1 filing relates to the resale of up to 9,306,072 shares of common stock of AIM ImmunoTech Inc. issuable upon exercise of warrants by the selling stockholder.

10-Q filing | 57.7M shares outstanding

8-K filing: AIM ImmunoTech Inc. entered into a Securities Purchase Agreement to issue 4,653,036 shares of common stock in a registered direct offering and Class C and Class D warrants to purchase up to 4,653,036 shares of its Common Stock each, for gross proceeds of approximately $1.26 million. ($1.26M proceeds)

10-Q filing | 52.8M shares outstanding

S-1 filing: This S-1 filing relates to the potential resale of up to 11,281,916 shares of AIM ImmunoTech Inc. common stock issuable upon the exercise of common warrants by a selling stockholder.

8-K filing: AIM ImmunoTech Inc. entered into a Securities Purchase Agreement to issue 5,640,958 shares of common stock in a registered direct offering and Class A and Class B common warrants to purchase up to 5,640,958 shares each in a concurrent private placement, with expected gross proceeds of approximately $2,047,688. ($2.05M proceeds)

10-Q filing | 49.5M shares outstanding

S-1 filing: This prospectus relates to the offer and resale of up to 9,975,000 shares of our Common Stock, par value $0.001 per share, by Atlas Sciences, LLC, which we refer to in this prospectus as Atlas or the selling stockholder.

10-K filing | 48.6M shares outstanding

10-Q filing | 48.6M shares outstanding

10-Q filing | 48.4M shares outstanding

10-Q filing | 48.4M shares outstanding

10-K filing | 48.4M shares outstanding

10-Q filing | 48.1M shares outstanding

10-Q filing | 48.0M shares outstanding

10-Q filing | 48.0M shares outstanding

10-K filing | 48.0M shares outstanding

S-3 filing: The filing is for a shelf registration allowing the company to offer and sell common stock, preferred stock, purchase contracts, subscription rights, depositary shares, and debt securities for gross proceeds up to $100,000,000.

POS AM filing: This is a POS AM filing by AIM Immunotech Inc. to deregister all unsold shares of common stock previously registered under Registration No. 333-226059.

10-Q filing | 47.8M shares outstanding

10-Q filing | 47.8M shares outstanding

10-Q filing | 42.2M shares outstanding

10-K filing | 10.4M shares outstanding

10-Q filing | 40.7M shares outstanding

10-Q filing | 39.7M shares outstanding

10-Q filing | 29.2M shares outstanding

10-K filing | 27.6M shares outstanding